Cell Biotech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Cell Biotech develops oral treatments for colorectal cancer using live bacteria, specifically, a genetically engineered lactic-acid bacterium designed to produce an anti-cancer protein directly inside the gut.
The company is listed on KOSDAQ, South Korea's tech and small-cap exchange, and its pipeline candidate is currently in a Phase One clinical trial at Seoul National University Hospital. Its drug-development work builds directly on its existing expertise in cultivating and commercialising lactic-acid bacterial strains, which it has developed over more than three decades.
Summary is AI-generated and may contain errors · figures from DART filings
The company has obtained a GMP (good manufacturing practice) licence for a biologics facility, allowing it to produce clinical-trial drug supply in-house using its own bacterial fermentation technology.
Cell Biotech in five facts
What does Cell Biotech do?
Cell Biotech develops oral treatments for colorectal cancer using live bacteria, specifically, a genetically engineered lactic-acid bacterium designed to produce an anti-cancer protein directly inside the gut.
Where is Cell Biotech listed and in which sector?
Cell Biotech (Korean name: 쎌바이오텍) trades under KRX code 049960 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Cell Biotech?
Its market capitalisation was US$108.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Cell Biotech's latest annual revenue and operating profit?
For fiscal year 2025, Cell Biotech reported revenue of US$40.1M, operating profit of US$6M and net income of US$7.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 6.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (consolidated) (preliminary) (fair disclosure)
Cell Biotech filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$11.1M (+32.8% year on year), operating profit of US$1.15M (+28% year on year) and net income of US$2.54M (+1589.4% year on year).
Earnings · Aug 7 - Operating results (consolidated) (preliminary) (fair disclosure)
Cell Biotech filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$10M (+30% year on year), operating profit of US$2.19M (+134% year on year) and net income of US$3.68M (+158.6% year on year).
Earnings · May 8 - Cash/in-kind dividend decision
Cell Biotech declared a cash dividend of US$0.41 per share.
Dividend · Feb 20 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Cell Biotech reported consolidated results for FY2025: revenue of US$36.8M (+6.8% year on year), operating profit of US$5.47M (+16.4% year on year) and net income of US$6.61M (−36.7% year on year).
Earnings · Feb 20